Filing Details

Accession Number:
0000899243-22-015653
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-26 16:15:12
Reporting Period:
2022-04-22
Accepted Time:
2022-04-26 16:15:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1840904 Atai Life Sciences N.v. ATAI Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1845711 Ltd. Group Investment Apeiron 66 &Amp; 67, Beatrice, Amery Street
Sliema O1 SLM1707
No No Yes No
1845872 Christian Angermayer 66 &Amp; 67, Beatrice, Amery Street
Sliema O1 SLM1707
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2022-04-22 52,820 $4.83 1,667,731 No 4 P Indirect By Apeiron Presight Capital Fund II, L.P.
Common Shares Acquisiton 2022-04-25 8,961 $4.78 1,676,692 No 4 P Indirect By Apeiron Presight Capital Fund II, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Apeiron Presight Capital Fund II, L.P.
No 4 P Indirect By Apeiron Presight Capital Fund II, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.77 to $4.90 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. The common shares were purchased in multiple transactions at prices ranging from $4.72 to $4.80 per share. The reporting persons undertake to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.